In the ever-evolving landscape of cancer treatment, targeted therapies have revolutionized patient care. Brigatinib, identified by its CAS number 1197958-12-5, stands out as a critical pharmaceutical intermediate and an active pharmaceutical ingredient (API) instrumental in these advancements, particularly for patients with ALK-positive non-small cell lung cancer (NSCLC). As a prominent pharmaceutical intermediate supplier in China, our focus is on delivering this high-value compound with exceptional purity and reliability.

Brigatinib's therapeutic efficacy stems from its ability to inhibit key proteins involved in cancer cell growth, specifically ALK and EGFR. This targeted approach offers a more precise and often more tolerable treatment option compared to traditional chemotherapy. For individuals diagnosed with ALK-rearranged NSCLC, Brigatinib represents a significant therapeutic option, aiming to halt disease progression and improve quality of life. The development of such targeted agents relies heavily on the consistent availability of high-quality APIs, making the role of manufacturers and suppliers like us indispensable. The CAS number 1197958-12-5 serves as a unique identifier for this crucial compound in the global pharmaceutical supply chain.

Our commitment as a supplier of Brigatinib API from China is to uphold the highest standards of quality. We provide a product that is over 98% pure and of pharmaceutical grade, available in a convenient powder form. This ensures that our clients, whether they are engaged in pharmaceutical manufacturing or cutting-edge research, receive a product that meets stringent industry requirements. The two-year shelf life of our Brigatinib API further adds to its practicality, allowing for better inventory management and long-term project planning. We understand that the integrity of the pharmaceutical intermediate directly impacts the success of the final therapeutic product.

The significance of Brigatinib as a pharmaceutical intermediate cannot be overstated. It is a building block for innovative treatments and a subject of ongoing research to explore its potential in other oncological indications. By specializing in the supply of CAS 1197958-12-5, we actively contribute to the progress of targeted oncology. Our mission as an ALK inhibitor manufacturer and supplier in China is to empower the pharmaceutical industry with the essential components needed to develop and deliver next-generation cancer therapies, ultimately contributing to better patient outcomes.